1. Dominguez F, Kuhl U, Pieske B, Garcia-Pavia P, Tschope C. Update
on myocarditis and inflammatory cardiomyopathy: reemergence of endomyocardial biopsy. Rev Esp Cardiol (Engl Ed). (2016) 69:178–87.
2. Tschope C, Ammirati E, Bozkurt B, Caforio ALP, Cooper LT, Felix SB, et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat Rev Cardiol. (2020) 12:1–25.
3. Cardoso R, Nasir K. Primary prevention of cardiovascular disease: 2019 and beyond. Nat Rev Cardiol. (2019) 16:387–8.
4. Rodrigues P, Santos-Ribeiro S, Teodoro T, Gomes FV, Leal I, Reis JP, Goff DC, Gonçalves A, Lima JAC. Association Between Alcohol Intake and Cardiac Remodeling. J Am Coll Cardiol. 2018 Sep 25;72(13):1452- 1462.
5. Ram P, Lo KB, Shah M, Patel B, Rangaswami J, Figueredo VM. National trends in hospitalizations and outcomes in patients with alcoholic cardiomyopathy. Clin Cardiol. 2018 Nov;41(11):1423-1429.
6. Fang W, Luo R, Tang Y, Hua W, Fu M, Chen W, Lai L, Li X. The Prognostic Factors of Alcoholic Cardiomyopathy: A single-center cohort study. Medicine (Baltimore). 2018 Aug;97(31): e11744.
7. McKenna WJ, Maron BJ, Thiene G. Classification, epidemiology, and global burden of cardiomyopathies. Circ Res. (2017) 121:722–30.
8. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. (2017) 390:1211–59.
9. Global burden of disease study 2019 (GBD 2019) results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME); 2020 [Internet]. Global Burden of Disease Collaborative Network. [cited 2021 Mar 14];
10. Institute for Health Metrics and Evaluation. The power of models [Internet]. Institute for Health Metrics and Evaluation; 2018 [cited 2019 Jul 30];
11. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. (2018) 392:1789–858.
12. Flaxman AD, Vos T, Murray CJL, editors. An integrative metaregression framework for descriptive epidemiology. Seattle: University of Washington Press; 2015.
13. GBD 2017 DALYs and HALE Collaborators. Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. (2018) 392:1859–922.
14. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. (2018) 392:1736–88.
15. GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioral, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. (2018) 392:1923–94.
16. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet [Internet] 2018; 392:1789–1858.
17. Hung GY, Horng JL, Yen HJ, Lee CY, Lin LY. Changing incidence patterns of hepatocellular carcinoma among age groups in Taiwan. J Hepatol 2015; 63:1390–1396.
18. Hankey BF, Ries LA, Kosary CL, et al. Partitioning linear trends in age-adjusted rates. Cancer Causes Control 2000; 11:31–5.
19. Falase AO, Ogah OS. Cardiomyopathies and myocardial disorders in Africa: present status and the way forward. Cardiovasc J Afr. (2012) 23:552–62.
20. Isogai T, Kamiya CA. Worldwide incidence of peripartum cardiomyopathy and overall maternal mortality. Int Heart J. (2019) 60:503–11.
21. Movsisyan NK, Vinciguerra M, Medina-Inojosa JR, Lopez-Jimenez F. Cardiovascular diseases in central and eastern europe: a call for more surveillance and evidence-based health promotion. Ann Glob Health. (2020) 86:21.
22. Peacock A, Leung J, Larney S, Colledge S, Hickman M, Rehm J, et al. Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. Addiction. (2018) 113:1905–26.
23. Rehm J, Zatonksi W, Taylor B, Anderson P. Epidemiology and alcohol policy in Europe. Addiction. (2011) 106:11–9.
24. GBD 2016 Alcohol Collaborators. Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. (2018) 392:1015–35.
25. Lipshultz SE, Cochran TR, Briston DA, Brown SR, Sambatakos PJ, Miller TL, et al. Pediatric cardiomyopathies: causes, epidemiology, clinical course, preventive strategies and therapies. Future Cardiol. (2013) 9:817–48.
26. Cheng X, Yang Y, Schwebel DC, Liu Z, Li L, Cheng P, et al. Population ageing and mortality during 1990–2017: a global decomposition analysis. PLoS Med. (2020) 17: e1003138.
27. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. (2006) 113:1807–16.